Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosin-kinase inhibitors: a real-world analysis

Abstract

Background and Aims: Front-line systemic therapy for patients with unresectable hepatocellular carcinoma (HCC) not amenable/responding to locoregional treatments includes, beside tyrosine-kinase inhibitors (TKIs) sorafenib and lenvatinib, the combination of atezolizumab-bevacizumab (Atezo-Beva) which has become the standard of care for these patients, showing a clear superiority on sorafenib in terms of overall survival (OS) and Quality of Life.